- Report
- October 2024
- 183 Pages
Global
From €3270EUR$3,545USD£2,773GBP
€3633EUR$3,939USD£3,081GBP
- Report
- October 2024
- 192 Pages
Global
From €3270EUR$3,545USD£2,773GBP
€3633EUR$3,939USD£3,081GBP
- Report
- February 2025
- 200 Pages
Global
From €4141EUR$4,490USD£3,512GBP
- Report
- May 2025
- 299 Pages
Global
From €5396EUR$5,850USD£4,576GBP
- Clinical Trials
- April 2025
- 220 Pages
Global
From €2306EUR$2,500USD£1,956GBP
- Report
- December 2024
- 171 Pages
Global
From €3643EUR$3,950USD£3,090GBP
- Report
- August 2024
- 168 Pages
Global
From €2306EUR$2,500USD£1,956GBP
- Report
- August 2024
- 49 Pages
Global
From €3685EUR$3,995USD£3,125GBP
- Report
- July 2024
- 100 Pages
Global
From €3459EUR$3,750USD£2,933GBP
- Report
- September 2024
- 343 Pages
Global
From €7333EUR$7,950USD£6,219GBP
- Report
- March 2025
- 175 Pages
Global
From €4141EUR$4,490USD£3,512GBP
- Report
- August 2024
- 200 Pages
Global
From €2297EUR$2,490USD£1,948GBP
- Report
- April 2025
- 150 Pages
Global
From €4473EUR$4,850USD£3,794GBP
- Report
- September 2024
- 128 Pages
Global
From €13831EUR$14,995USD£11,730GBP
- Report
- April 2025
- 133 Pages
Global
From €13831EUR$14,995USD£11,730GBP
- Report
- April 2025
- 21 Pages
Global
From €13831EUR$14,995USD£11,730GBP
- Report
- May 2020
- 185 Pages
Global
From €3828EUR$4,150USD£3,246GBP
- Report
- March 2022
- 300 Pages
Global
From €4612EUR$5,000USD£3,911GBP
- Report
- January 2023
- 125 Pages
Global
From €2297EUR$2,490USD£1,948GBP
- Report
- January 2024
- 150 Pages
Global
From €4473EUR$4,850USD£3,794GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more